Table 2 Prevalence of carbapenem resistance among Gram-negative bacteria isolated from clinical samples in selected national and international surveillance networks
Surveillance network | CHINET | CDC/NHSN | SENTRY | SENTRY | SENTRY | EB-2 | EARS-Net | SPIADI | SPIADI |
|---|---|---|---|---|---|---|---|---|---|
Geographical area | China | USA | USA | Western Europe | Eastern Europe | Worldwide | Europe | France | France |
Sample collection, period | 2016 | 2015–2017 | 2016–2019 | 2016–2019 | 2016–2019 | 2019–2020 | 2021 | 2021 | 2021 |
Infection type | HA-BSI | DA-HAI | Pneumonia a | Pneumoniaa | Pneumoniaa | HA-BSI (ICU) | Allb | VAP (ICU) | HA-CR-BSI |
References | [20] | [21] | [22] | [22] | [22] | [23] | [8] | [211] | [211] |
Enterobacterales Escherichia coli Klebsiella pneumoniae | – 1.6% 42.9% | – 0.7% 6.9% | – 0.5% 4.7% | – 0.4% 8.7% | – 0.5% 17.5% | – 7.4% 37.8% | – 0.2% 11.7% | – – – | 0.6% – – |
Pseudomonas aeruginosa | 24.3% | 20.7% | 25.2% | 23.1% | 51.7% | 33.2% | 18.1% | 20.8% | 9.0% |
Acinetobacter baumannii | 57.7% | 43.2% | 41.2% | 54.2% | 89.6% | 84.6% | 39.9% | 22.8% | – |